Vapotherm, Inc. (VAPO)
OTCMKTS: VAPO · Delayed Price · USD
1.198
-0.002 (-0.20%)
May 1, 2024, 2:25 PM EDT - Market closed
Vapotherm Revenue
In the year 2023, Vapotherm had annual revenue of $68.67M with 2.80% growth. Revenue in the quarter ending December 31, 2023 was $19.73M with 5.74% year-over-year growth.
Revenue (ttm)
$68.67M
Revenue Growth
+2.80%
P/S Ratio
0.11
Revenue / Employee
$377,302
Employees
182
Market Cap
7.87M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 68.67M | 1.87M | 2.80% |
Dec 31, 2022 | 66.80M | -46.49M | -41.04% |
Dec 31, 2021 | 113.29M | -12.44M | -9.89% |
Dec 31, 2020 | 125.73M | 77.63M | 161.38% |
Dec 31, 2019 | 48.10M | 5.73M | 13.51% |
Dec 31, 2018 | 42.38M | 6.78M | 19.05% |
Dec 31, 2017 | 35.60M | 5.48M | 18.18% |
Dec 31, 2016 | 30.12M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 371.62B |
Johnson & Johnson | 85.16B |
Merck & Co. | 60.12B |
AbbVie | 54.32B |
Novartis AG | 49.92B |
AstraZeneca | 47.61B |
Thermo Fisher | 42.86B |
Abbott Laboratories | 40.11B |
VAPO News
- 6 weeks ago - Onymos and Vapotherm Announce Partnership to Create an End-to-End Internet of Medical Things Solution (IoMT) - PRNewsWire
- 6 weeks ago - Vapotherm to Unveil Access365 Home Ventilation Solution at MEDTRADE - PRNewsWire
- 2 months ago - Dr. David Yamane was awarded the Star Research Award at the 2024 Critical Care Congress for the presentation of the HYPERACT Study - a randomized controlled trial demonstrating Vapotherm's High Velocity Therapy effectively treats moderate-severe acute exacerbations of COPD, while improving patient comfort - PRNewsWire
- 2 months ago - Vapotherm's HVT 2.0 System Overcomes Regulatory Hurdles for Entry into South America's Largest Health Care Market - PRNewsWire
- 2 months ago - Vapotherm Reports Fourth Quarter and Fiscal Year 2023 Financial Results - PRNewsWire
- 5 months ago - Vapotherm Announces Suspension of NYSE Listing Common Stock Expected to Begin Trading Promptly on OTCQX - PRNewsWire
- 5 months ago - NYSE to Commence Delisting Proceedings Against Vapotherm, Inc. (VAPO) - Business Wire
- 5 months ago - Vapotherm Announces Notification to New York Stock Exchange of Intention to Voluntarily Delist Common Stock Application Pending to Transfer Shares to OTCQX - PRNewsWire